LON:DEST Destiny Pharma (DEST) Share Forecast, Price & News GBX 29.80 0.00 (0.00%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range 29.62▼ 3050-Day Range 28▼ 3652-Week Range 27▼ 61.85Volume188,723 shsAverage Volume376,087 shsMarket Capitalization£28.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions ChainProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesOptions Chain About Destiny Pharma (LON:DEST) StockDestiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.Read More Receive DEST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address DEST Stock News HeadlinesMay 28, 2023 | americanbankingnews.comDestiny Pharma plc (LON:DEST) Insider Nick Rodgers Acquires 49,477 SharesMay 25, 2023 | marketwatch.comDestiny Pharma CEO Steps Down; Debra Barker Named as Interim ReplacementJune 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 25, 2023 | proactiveinvestors.comDestiny Pharma chief steps downMay 2, 2023 | proactiveinvestors.comDestiny Pharma's C.diffcile treatment on path to commercial successMay 2, 2023 | marketwatch.comDestiny Pharma Gets Positive Results For Covid-19 Nasal SprayMay 2, 2023 | proactiveinvestors.comDestiny Pharma reveals significant progress with Covid and flu sprayMay 2, 2023 | proactiveinvestors.comDestiny Pharma's nasal spray project already delivering "more than hoped for"June 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.April 18, 2023 | proactiveinvestors.comDestiny Pharma says XF-73 now "very well positioned" for a partnering programmeApril 16, 2023 | americanbankingnews.comDestiny Pharma's (DEST) "House Stock" Rating Reiterated at Shore CapitalApril 14, 2023 | proactiveinvestors.comDestiny Pharma's almost 1,000% upside target reiterated by finnCapApril 13, 2023 | proactiveinvestors.comDestiny Pharma focused on delivering further dealsApril 6, 2023 | proactiveinvestors.comDestiny Pharma upbeat on prospects for C. Difficile treatmentApril 5, 2023 | proactiveinvestors.comDestiny Pharma broker upbeat on latest data for key assetApril 4, 2023 | proactiveinvestors.comDestiny Pharma hails latest peer-reviewed research on CDI assetMarch 27, 2023 | americanbankingnews.comDestiny Pharma (LON:DEST) Earns "House Stock" Rating from Shore CapitalMarch 24, 2023 | proactiveinvestors.comDestiny Pharma looking to move on to phase III with XF-73 nasal gelMarch 24, 2023 | proactiveinvestors.comDestiny Pharma nasal gel results showcased in leading journalMarch 15, 2023 | marketwatch.comDestiny Pharma Raised GBP340,000 via Open Offer; Missed GBP8 Mln Fundraising TargetMarch 6, 2023 | proactiveinvestors.comDestiny Pharma "making real progress"February 18, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Destiny Pharma's (LON:DEST) Cash Burn SituationFebruary 17, 2023 | marketwatch.comBurns Treatment Market 2023 Size Industry, Current Trends, Demand and Size Share Estimation by 2028 with Top PlayersFebruary 15, 2023 | finance.yahoo.comPoxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate UpdateFebruary 10, 2023 | marketwatch.comBurns Treatment Market Share Likely to Grow At a CAGRFebruary 4, 2023 | msn.comDestiny's childJanuary 27, 2023 | finance.yahoo.comPharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study EndsSee More Headlines DEST Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DEST Company Calendar Last Earnings9/17/2020Today6/03/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:DEST CUSIPN/A CIKN/A Webwww.destinypharma.com Phone+44-1273-704440FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-6,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-85.94% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio11.10 Sales & Book Value Annual Sales£135,028.00 Price / Sales210.23 Cash FlowGBX 11.08 per share Price / Cash Flow2.69 Book ValueGBX 10 per share Price / Book2.98Miscellaneous Outstanding Shares95,260,000Free FloatN/AMarket Cap£28.39 million OptionableOptionable Beta0.36 Key ExecutivesMr. Neil Robert Clark (Age 60)CEO & Director Comp: $303kDr. William Guy Love (Age 60)Founder, Chief Scientific Officer & Director Comp: $252kMr. Shaun Claydon ACA (Age 55)CFO, Company Sec. & Director Comp: $271kDr. Stephanie BewickChief Bus. OfficerDr. Yuri Martina M.B.A.M.D., Chief Medical OfficerKey CompetitorsNovacytLON:NCYTSkinBioTherapeuticsLON:SBTX4D pharmaLON:DDDDOndine BiomedicalLON:OBIHemogenyx PharmaceuticalsLON:HEMOView All CompetitorsInsidersNick RodgersBought 49,477 shares on 5/25/2023Total: £1.53 M ($31.00/share)Nick RodgersBought 20,000 shares on 2/27/2023Total: £680,000.00 ($34.00/share)View All Insider Transactions DEST Stock - Frequently Asked Questions How have DEST shares performed in 2023? Destiny Pharma's stock was trading at GBX 53.50 at the beginning of the year. Since then, DEST stock has decreased by 44.3% and is now trading at GBX 29.80. View the best growth stocks for 2023 here. How were Destiny Pharma's earnings last quarter? Destiny Pharma plc (LON:DEST) posted its earnings results on Thursday, September, 17th. The company reported ($5.50) earnings per share (EPS) for the quarter. What other stocks do shareholders of Destiny Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT). What is Destiny Pharma's stock symbol? Destiny Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DEST." How do I buy shares of Destiny Pharma? Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Destiny Pharma's stock price today? One share of DEST stock can currently be purchased for approximately GBX 29.80. How much money does Destiny Pharma make? Destiny Pharma (LON:DEST) has a market capitalization of £28.39 million and generates £135,028.00 in revenue each year. The company earns £-6,500,000.00 in net income (profit) each year or GBX (0.09) on an earnings per share basis. How can I contact Destiny Pharma? Destiny Pharma's mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The official website for the company is www.destinypharma.com. The company can be reached via phone at +44-1273-704440. This page (LON:DEST) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Destiny Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.